Skip to main content
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ARMP ISIN · US04216R1023 LEI · 549300QM1VCWH8KT0S21 US Manufacturing
Open in API
Filings indexed 1,011 across all filing types
Latest filing 2009-09-11 Director's Dealing
Country US United States of America
Listing US ARMP

About Armata Pharmaceuticals, Inc.

https://www.armatapharma.com/

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2009-09-11 English
FORM 8-K FOR GENZYME ASSET SALE
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the sale of assets (an asset purchase agreement) between Targeted Genetics Corporation and Genzyme Corporation, including details of the transaction, payments, and termination of a prior agreement. This is a typical disclosure of a material definitive agreement and completion of disposition of assets. It is not a full financial report, earnings release, or management discussion, but rather a regulatory announcement of a significant transaction. Therefore, the appropriate classification is a Regulatory Filing (RNS), which is the fallback category for such SEC current reports that do not fit other specific categories.
2009-09-09 English
FORM 8-K FOR ADDITIONAL NASDAQ NOTICE
Delisting Announcement Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated August 10, 2009, by Targeted Genetics Corporation. The content focuses on a Nasdaq notice regarding the company's failure to meet listing requirements, specifically the bid price and shareholders' equity requirements, and the potential delisting of the company's stock. The document is short (3652 characters) and serves as an official announcement of a regulatory event related to the company's stock listing status. It is not a full financial report, audit, earnings release, or management discussion. The primary subject is the notice of delisting or potential delisting from Nasdaq. Therefore, the appropriate classification is a Delisting Announcement (DLST).
2009-08-14 English
FORM 10-Q
Interim / Quarterly Report Q2 2009
2009-08-12 English
FORM 8-K FOR Q2 2009 EARNINGS RELEASE
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, specifically reporting the earnings release for Q2 2009. It includes a press release announcing financial results for the quarter ended June 30, 2009. The document is relatively short (2421 characters) and primarily serves as an announcement of quarterly financial results rather than a full detailed report. The key phrase 'Results of Operations and Financial Condition' and the inclusion of a press release indicate this is an Earnings Release filing. Therefore, the appropriate classification is Earnings Release (ER).
2009-08-12 English
Regulatory Filings 2009
Regulatory Filings
2009-08-12 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.